165 related articles for article (PubMed ID: 33341450)
1. Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer.
den Uil SH; de Wit M; Slebos RJC; Delis-van Diemen PM; Sanders J; Piersma SR; Pham TV; Coupé VMH; Bril H; Stockmann HBAC; Jimenez CR; Meijer GA; Fijneman RJA
Eur J Cancer; 2021 Feb; 144():91-100. PubMed ID: 33341450
[TBL] [Abstract][Full Text] [Related]
2. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract][Full Text] [Related]
3. CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer.
Cecchini MJ; Walsh JC; Parfitt J; Chakrabarti S; Correa RJ; MacKenzie MJ; Driman DK
Hum Pathol; 2019 Aug; 90():70-79. PubMed ID: 31121192
[TBL] [Abstract][Full Text] [Related]
4. Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.
Derangère V; Lecuelle J; Lepage C; Aoulad-Ben Salem O; Allatessem BM; Ilie A; Bouché O; Phelip JM; Baconnier M; Pezet D; Sebbagh V; Terrebonne E; Bouard G; Jooste V; Bouvier AM; Molimard C; Monnien F; Gonzalez D; Le Malicot K; Rageot D; Truntzer C; Bibeau F; Ghiringhelli F;
Eur J Cancer; 2022 Sep; 172():221-230. PubMed ID: 35785606
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts.
Hansen TF; Kjær-Frifeldt S; Eriksen AC; Lindebjerg J; Jensen LH; Sørensen FB; Jakobsen A
Br J Cancer; 2018 Nov; 119(11):1367-1373. PubMed ID: 30425348
[TBL] [Abstract][Full Text] [Related]
6. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data.
Aydin SG; Olmez OF; Selvi O; Geredeli C; Ozden F; Bilici A; Acikgoz O; Karci E; Kutlu Y; Hamdard J; Aydin A
J Gastrointest Cancer; 2024 Mar; 55(1):227-236. PubMed ID: 37347353
[TBL] [Abstract][Full Text] [Related]
8. Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer.
Hestetun KE; Aasebø K; Rosenlund NB; Müller Y; Dahl O; Myklebust MP
Mod Pathol; 2021 Jan; 34(1):161-170. PubMed ID: 32737450
[TBL] [Abstract][Full Text] [Related]
9. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
[TBL] [Abstract][Full Text] [Related]
10. An exploration of immunohistochemistry-based prognostic markers in patients undergoing curative resections for colon cancer.
Bennedsen ALB; Cai L; Hasselager RP; Özcan AA; Mohamed KB; Eriksen JO; Eiholm S; Bzorek M; Fiehn AK; Hviid TVF; Gögenur I
BMC Cancer; 2022 Jan; 22(1):62. PubMed ID: 35027037
[TBL] [Abstract][Full Text] [Related]
11. Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancer.
Xu W; Zhu Y; Shen W; Ding W; Wu T; Guo Y; Chen X; Zhou M; Chen Y; Cui L; Du P
J Int Med Res; 2019 May; 47(5):1829-1842. PubMed ID: 30616445
[TBL] [Abstract][Full Text] [Related]
12. CDX2 Protein Expression in Colorectal Cancer and ItsCorrelation with Clinical and Pathological Characteristics, Prognosis, and Survival Rate of Patients.
Asgari-Karchekani S; Karimian M; Mazoochi T; Taheri MA; Khamehchian T
J Gastrointest Cancer; 2020 Sep; 51(3):844-849. PubMed ID: 31630373
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of CDX2 and Villin Expression in Advanced Stage Colorectal Carcinoma.
Altintas S; Bayrak M; Altintas Y
J Coll Physicians Surg Pak; 2019 Nov; 29(11):1057-1061. PubMed ID: 31659962
[TBL] [Abstract][Full Text] [Related]
14. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma.
Slik K; Turkki R; Carpén O; Kurki S; Korkeila E; Sundström J; Pellinen T
Am J Surg Pathol; 2019 Nov; 43(11):1473-1482. PubMed ID: 31490234
[TBL] [Abstract][Full Text] [Related]
15. Retinoic acid-induced protein 3: identification and characterisation of a novel prognostic colon cancer biomarker.
Zougman A; Hutchins GG; Cairns DA; Verghese E; Perry SL; Jayne DG; Selby PJ; Banks RE
Eur J Cancer; 2013 Jan; 49(2):531-9. PubMed ID: 23021913
[TBL] [Abstract][Full Text] [Related]
16. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients.
Ribeirinho-Soares S; Pádua D; Amaral AL; Valentini E; Azevedo D; Marques C; Barros R; Macedo F; Mesquita P; Almeida R
BMC Cancer; 2021 Apr; 21(1):359. PubMed ID: 33823840
[TBL] [Abstract][Full Text] [Related]
18. CDX2 downregulation is associated with poor differentiation and MMR deficiency in colon cancer.
Olsen J; Eiholm S; Kirkeby LT; Espersen ML; Jess P; Gögenür I; Olsen J; Troelsen JT
Exp Mol Pathol; 2016 Feb; 100(1):59-66. PubMed ID: 26551082
[TBL] [Abstract][Full Text] [Related]
19. CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification.
Pilati C; Taieb J; Balogoun R; Marisa L; de Reyniès A; Laurent-Puig P
Ann Oncol; 2017 May; 28(5):1032-1035. PubMed ID: 28328000
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of Src activation in stage II-III colon cancer.
Martínez-Pérez J; Lopez-Calderero I; Saez C; Benavent M; Limon ML; Gonzalez-Exposito R; Soldevilla B; Riesco-Martínez MC; Salamanca J; Carnero A; Garcia-Carbonero R
Hum Pathol; 2017 Sep; 67():119-125. PubMed ID: 28601656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]